Pharma, Biotech and Generics Industry News | The Pharmaletter
Jan 2, 2025 · Up to date news for the pharmaceutical and biotechnology industries - The Pharma Letter
Pharma USA 2025 - The Pharmaletter
A leading meeting for commercial, marketing, medical affairs, patient engagement, RWE, market access and patient leaders.
Second FDA approval for BeiGene’s Tevimbra in 2024
Dec 27, 2024 · The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for …
Positive Phase III trials results with BMS’ Sotyktu
Dec 24, 2024 · US pharma major Bristol Myers Squibb has announced positive results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), the pivotal Phase III trials …
Pfizer unveils new China strategy with $1 billion investment
Nov 8, 2024 · Pfizer plans to invest $1 billion in China by 2030 to support innovation, diagnostics, and the biotech sector, aligning with China’s “Healthy China 2030” initiative. This includes an …
First ‘Breakthrough’ designation for datopotamab deruxtecan
Dec 9, 2024 · Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of adult …
Uncertain future for S1P receptor modulators in Crohn’s disease, …
Oct 11, 2024 · Pfizer (NYSE: PFE) is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease …
FDA generic drug science and research priorities for 2025
Nov 28, 2024 · The US Food and Drug Administration (FDA) yesterday announced its Fiscal Year 2025 Generic Drug User Fee Amendments (GDUFA). The FDA determined the priority …
Relation’s $45 million upfront GSK collaboration all part of right ...
Dec 23, 2024 · Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront …
NewAmsterdam leaps on positive trial results | The Pharmaletter
Dec 11, 2024 · Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research results for its cholesterol lower obicetrapib.